Supreme Critical Metals Announces Closing of Second and Final Tranche of LIFE Offering
aTyr PharmaaTyr Pharma(US:LIFE) TMX Newsfile·2026-02-17 10:00

Core Viewpoint - Supreme Critical Metals Inc. has successfully closed the final tranche of its non-brokered private placement financing, raising a total of $1,141,000 through the issuance of 11,410,000 units, exceeding the initial target by 14.1% [3]. Financing Details - The second and final tranche of the LIFE Offering involved the issuance of 1,730,000 units at a price of $0.10 per unit, with each unit comprising one common share and one-half of a common share purchase warrant [2]. - Each whole warrant allows the holder to acquire an additional common share at a price of $0.20 for a period of 24 months from the closing of this tranche [2]. - The total gross proceeds from the LIFE Offering amounted to $1,141,000, with the offering being oversubscribed at a rate of 114.1% compared to the originally announced maximum of 10,000,000 units [3]. Use of Proceeds - The net proceeds from the LIFE Offering will be utilized for general corporate and working capital purposes, as detailed in the Offering Document [5]. Regulatory Approval - The closing of the LIFE Offering received conditional approval from the Canadian Securities Exchange (CSE), and the securities issued will not be subject to a four-month and one-day statutory hold period [5]. Company Overview - Supreme Critical Metals Inc. is a publicly traded diversified investment corporation focused on exploring opportunities in lithium, copper, silver, and precious metals, operating in regions favorable for mining [7].

aTyr Pharma-Supreme Critical Metals Announces Closing of Second and Final Tranche of LIFE Offering - Reportify